Menu
X
doctor.huang@globecancer.com Become Our Partner Get Free Help

Tags Archives: ADC Drug


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
2 months ago Solid tumor

Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials!

Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials!

ADC

ADC

#ADC #Immunotherapy#B7H3 #LungCancer #HeadAndNeckCancer #ADCDrug

On September 20, the China National Medical Products Administration (NMPA) approved BeiGene’s innovative anti-cancer drug, BGB-C354, for clinical trials. This exciting news marks the first approval for clinical research of this novel molecule in China. BGB-C354 is an Antibody-Drug Conjugate (ADC) specifically designed to target B7-H3, a protein often overexpressed in various cancers such as lung cancer, prostate cancer, breast cancer, and squamous cell carcinoma of the head and neck.

BGB-C354 holds significant promise for treating patients with advanced solid tumors, particularly lung cancer and head and neck squamous cell carcinoma (HNSCC). B7-H3 has gained attention as a key anti-cancer target, with its high expression often linked to poor prognosis. By leveraging the power of ADC technology, BGB-C354 aims to selectively deliver potent anti-cancer drugs directly to tumor cells, minimizing damage to healthy cells.

BeiGene has already initiated a Phase 1 clinical trial in the US and Australia, evaluating the safety, tolerability, and preliminary anti-tumor activity of BGB-C354 as a monotherapy and in combination with anti-PD-1 antibody, Tislelizumab. This recent approval sets the stage for the commencement of clinical trials in China.

Globally, B7-H3-targeted therapies are advancing rapidly. Companies like Daiichi Sankyo, Merck, and GSK are pushing the boundaries with their ADCs, entering Phase 2 and 3 clinical trials. The approval of BGB-C354 marks a significant step in advancing cancer treatment options in China, offering new hope for patients with difficult-to-treat cancers.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #ClinicalTrials #BeiGene #OncologyBreakthrough #PharmaInnovation #CancerResearch


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
3 months ago Solid tumor

**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau**

**A Groundbreaking ADC Drug for Cervical Cancer Approved in China Macau**

Cervical Cancer

Cervical Cancer

On August 6, 2024, Zai Lab proudly announced the approval of TIVDAK® (tisotumab vedotin-tftv) in Macau, marking the world’s first ADC (antibody-drug conjugate) specifically for cervical cancer. This innovative treatment is intended for patients with recurrent or metastatic cervical cancer who have experienced disease progression during or after chemotherapy.

TIVDAK stands as a significant milestone, being the first ADC drug approved by the FDA for cervical cancer. Following its accelerated approval in 2021, the FDA granted full approval in April 2024, solidifying its use for patients needing treatment after chemotherapy failure.

The FDA’s full approval was backed by positive outcomes from the global Phase 3 clinical trial, innovaTV 301. This study demonstrated that patients treated with TIVDAK experienced an overall survival benefit compared to those receiving chemotherapy. This finding is particularly noteworthy, as TIVDAK is the first ADC drug globally to show clear survival benefits for patients with second and third-line metastatic or recurrent cervical cancer.

Cervical cancer remains a leading threat in women’s health. Despite advancements in prevention through vaccination and early diagnosis via screening, there remains a significant unmet need for effective treatments. In China alone, an estimated 150,000 new cases are diagnosed each year, with approximately 60,000 fatalities. At the time of diagnosis, around 15% of adult patients have metastatic disease. For those diagnosed early and receiving treatment, up to 61% experience recurrence.

Zai Lab is participating in the global innovaTV 301 study and anticipates submitting a marketing application in China by early 2025. This approval in Macau represents a significant step forward in providing new hope for cervical cancer patients worldwide.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CervicalCancer #ADCDrug #TIVDAK #ZaiLab #CancerTreatment #WomenHealth #MedicalAdvancement #FDAApproval #ClinicalTrial #Macau #GlobalHealth #InnovativeTherapy #PatientCare #Pharmaceuticals

Recent Posts

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.